Literature DB >> 10541293

Aberrant splicing in the PKD2 gene as a cause of polycystic kidney disease.

D M Reynolds1, T Hayashi, Y Cai, B Veldhuisen, T J Watnick, X M Lens, T Mochizuki, F Qian, Y Maeda, L Li, R Fossdal, E Coto, G Wu, M H Breuning, G G Germino, D J Peters, S Somlo.   

Abstract

It is estimated that approximately 15% of families with autosomal dominant polycystic kidney disease (ADPKD) have mutations in PKD2. Identification of these mutations is central to identifying functionally important regions of gene and to understanding the mechanisms underlying the pathogenesis of the disorder. The current study describes mutations in six type 2 ADPKD families. Two single base substitution mutations discovered in the ORF in exon 14 constitute the most COOH-terminal pathogenic variants described to date. One of these mutations is a nonsense change and the other encodes an apparent missense variant. Reverse transcription-PCR from patient lymphoblast RNA showed that, in addition, both mutations resulted in out-of-frame splice variants by activating cryptic splice sites via different mechanisms. The apparent missense variant produced such a strong splicing signal that the processed transcript from the mutant chromosome did not contain any of the normally spliced, missense product. A third mutation, a nonconservative missense change effecting a negatively charged residue in the third transmembrane span, is likely pathogenic and defines a highly conserved residue consistent with a potential channel subunit function for polycystin-2. The remaining three mutations included two frame shifts resulting from deletion of one or two bases in exons 6 and 10, respectively, and a nonsense mutation due to a single base substitution in exon 4. The study also defined a novel intragenic polymorphism in exon 1 that will be useful in analyzing "second hits" in PKD2. Finally, the study demonstrates that there are reduced levels of normal polycystin-2 protein in lymphoblast lines from PKD2-affected individuals and that truncated mutant polycystin-2 cannot be detected in patient lymphoblasts, suggesting that the latter may be unstable in at least some tissues. The mutations described will serve as critical reagents for future functional studies in PKD2.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541293     DOI: 10.1681/ASN.V10112342

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

1.  Altered trafficking and stability of polycystins underlie polycystic kidney disease.

Authors:  Yiqiang Cai; Sorin V Fedeles; Ke Dong; Georgia Anyatonwu; Tamehito Onoe; Michihiro Mitobe; Jian-Dong Gao; Dayne Okuhara; Xin Tian; Anna-Rachel Gallagher; Zhangui Tang; Xiaoli Xie; Maria D Lalioti; Ann-Hwee Lee; Barbara E Ehrlich; Stefan Somlo
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 3.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

4.  Formation of a new receptor-operated channel by heteromeric assembly of TRPP2 and TRPC1 subunits.

Authors:  Chang-Xi Bai; Aurélie Giamarchi; Lise Rodat-Despoix; Françoise Padilla; Tamyra Downs; Leonidas Tsiokas; Patrick Delmas
Journal:  EMBO Rep       Date:  2008-03-07       Impact factor: 8.807

Review 5.  Function and regulation of TRPP2 at the plasma membrane.

Authors:  Leonidas Tsiokas
Journal:  Am J Physiol Renal Physiol       Date:  2009-02-25

6.  Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition.

Authors:  Alexis Hofherr; Claudius J Wagner; Terry Watnick; Michael Köttgen
Journal:  Kidney Int       Date:  2016-01-06       Impact factor: 10.612

7.  Evaluating the clinical utility of a molecular genetic test for polycystic kidney disease.

Authors:  Miguel A Garcia-Gonzalez; Jeffrey G Jones; Susan K Allen; Christopher M Palatucci; Sat D Batish; William K Seltzer; Zheng Lan; Erica Allen; Feng Qian; Xose M Lens; York Pei; Gregory G Germino; Terry J Watnick
Journal:  Mol Genet Metab       Date:  2007-06-18       Impact factor: 4.797

8.  Genomic features defining exonic variants that modulate splicing.

Authors:  Adam Woolfe; James C Mullikin; Laura Elnitski
Journal:  Genome Biol       Date:  2010-02-16       Impact factor: 13.583

9.  Polycystin-1 C-terminal cleavage is modulated by polycystin-2 expression.

Authors:  Claudia A Bertuccio; Hannah C Chapin; Yiqiang Cai; Kavita Mistry; Veronique Chauvet; Stefan Somlo; Michael J Caplan
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

10.  Domain mapping of the polycystin-2 C-terminal tail using de novo molecular modeling and biophysical analysis.

Authors:  Andjelka Celić; Edward T Petri; Borries Demeler; Barbara E Ehrlich; Titus J Boggon
Journal:  J Biol Chem       Date:  2008-08-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.